You are here

  • Home
  • Archive
  • Volume 66, Issue Suppl 2
  • AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study

Citation Tools

Article menu
Download PDFPDF
Inflammatory Bowel Disease
AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kaser A, James A, on behalf of the GEMINI open-label extension study authors
AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study
Gut 2017;66:A120.